154 related articles for article (PubMed ID: 8547463)
1. No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
Silver H; Geraisy N
Biol Psychiatry; 1995 Sep; 38(6):413-5. PubMed ID: 8547463
[No Abstract] [Full Text] [Related]
2. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
3. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
[No Abstract] [Full Text] [Related]
4. Effect of anticholinergics on positive and negative symptoms in schizophrenia.
Tandon R; DeQuardo JR; Goodson J; Mann NA; Greden JF
Psychopharmacol Bull; 1992; 28(3):297-302. PubMed ID: 1480733
[TBL] [Abstract][Full Text] [Related]
5. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study.
Silver H; Geraisy N
Br J Psychiatry; 1995 Feb; 166(2):241-3. PubMed ID: 7728369
[TBL] [Abstract][Full Text] [Related]
6. [Dependence on anticholinergics among schizophrenics. Iatrogenic disease or self-medication?].
Chamorro García L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1991; 19(6):298-303. PubMed ID: 1687233
[TBL] [Abstract][Full Text] [Related]
7. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
[TBL] [Abstract][Full Text] [Related]
8. The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study.
Gerbaldo H; Demisch L; Lehmann CO; Bochnik J
Pharmacopsychiatry; 1988 Nov; 21(6):387-8. PubMed ID: 2907646
[No Abstract] [Full Text] [Related]
9. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders.
König P; Chwatal K; Havelec L; Riedl F; Schubert H; Schultes H
Neuropsychobiology; 1996; 33(2):80-4. PubMed ID: 8927233
[TBL] [Abstract][Full Text] [Related]
10. Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group.
Glick ID; Jacobs M; Lieberman J; Simpson G; Schooler NR
Psychopharmacol Bull; 1989; 25(3):344-7. PubMed ID: 2626513
[No Abstract] [Full Text] [Related]
11. Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients.
Valevski A; Modai I; Zbarski E; Zemishlany Z; Weizman A
Clin Neuropharmacol; 1998; 21(6):355-7. PubMed ID: 9844793
[TBL] [Abstract][Full Text] [Related]
12. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.
Jellinek T
Dis Nerv Syst; 1977 May; 38(5):353-5. PubMed ID: 852367
[TBL] [Abstract][Full Text] [Related]
13. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics.
Olbrich R; Schanz H
Pharmacopsychiatry; 1988 Nov; 21(6):389-90. PubMed ID: 2907647
[No Abstract] [Full Text] [Related]
14. Amineptine treatment of persistent catatonic symptoms in schizophrenia: a controlled study.
Ungvari GS
Neuropsychopharmacol Hung; 2010 Dec; 12(4):463-7. PubMed ID: 21220791
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients.
Silver H; Goodman C; Isakov V; Knoll G; Modai I
Int Clin Psychopharmacol; 2005 Nov; 20(6):319-26. PubMed ID: 16192841
[TBL] [Abstract][Full Text] [Related]
16. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
17. A double-blind comparison of pimozide vs. trifluoperazine in schizophrenic outpatients.
Claghorn JL
Curr Ther Res Clin Exp; 1974 Sep; 16(9):1005-9. PubMed ID: 4214658
[No Abstract] [Full Text] [Related]
18. Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study.
Silver H; Geraisy N
J Clin Psychopharmacol; 1996 Dec; 16(6):463-4. PubMed ID: 8959477
[No Abstract] [Full Text] [Related]
19. Changes in verbal learning of patients with schizophrenia: Results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics.
Czepielewski LS; Sodré L; Souza AC; Bücker J; Burke KP; Ceresér KM; Gama CS
Schizophr Res; 2015 Oct; 168(1-2):571-2. PubMed ID: 26104472
[No Abstract] [Full Text] [Related]
20. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia.
Levine J; Stahl Z; Sela BA; Ruderman V; Shumaico O; Babushkin I; Osher Y; Bersudsky Y; Belmaker RH
Biol Psychiatry; 2006 Aug; 60(3):265-9. PubMed ID: 16412989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
